Skip to main content

Table 3 Subgroup analyses of the relationships between CD133 ovexpression and overall survival or progression-free-survival

From: Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis

Comparison variables Overall survival Progression-free survival
Number of studies, Heterogeneity (I2 statistics; %) HR 95 % CI, P value Interaction, P value Number of studies, Heterogeneity (I2 statistics; %) HR 95 % CI, P value Interaction, P value
Total 11 (77.8) 1.69 (1.16–2.47), 0.006 NA 8 (68.2) 1.64 (1.12–2.39), 0.010 NA
Origin country       
Europe 8 (81.0) 1.63 (1.03–2.61), 0.039 0.030 6 (76.5) 1.74 (1.06–2.83), 0.027 0.579
Asian 3 (42.5) 1.85 (1.02–3.35), 0.044   2 (0.0) 1.37 (0.86–2.18), 0.188  
Sample size       
>50 4 (77.4) 1.45 (0.91–2.31), 0.116 0.000 3 (0.0) 1.37 (1.01–1.73), 0.009 0.092
≤50 7 (67.6) 1.94 (1.07–3.54), 0.030   5 (77.0) 1.99 (0.94–4.22), 0.073  
Follow up period       
1,>media 12months 4 (74.1) 2.48 (1.13–5.45), 0.024 0.000 3 (86.7) 2.64 (0.98–7.11), 0.054 0.060
2,≤media 12months 3 (43.0) 0.90 (0.54–1.49), 0.678   3 (0.0) 1.12 (0.79–1.57), 0.530  
3,No Referreed 4 (0) 2.11 (1.52–2.93), 0.000   2 (0.0) 1.64 (1.19–2.27), 0.003
Median/mean age y       
Referred 6 (0.0) 1.85 (1.45–2.37), 0.000 0.000 3 (0.0) 1.59 (1.24–2.04), 0.000 0.713
No Referred 5 (79.8) 1.57 (0.70–3.55), 0.274   5 (80.8) 1.79 (0.81–3.97), 0.153  
Test method       
IHC 5 (64.8) 2.16 (1.25–3.73), 0.006 0.000 4 (80.9) 2.25 (1.11–4.58), 0.025 0.122
Others 6 (71.2) 1.37 (0.85–2.22), 0.202   4 (20.4) 1.31 (0.93–1.84), 0.122  
Cut‑off level       
1:median 4 (61.4) 1.09 (0.66–1.79) 0.748 0.000 3 (0.0) 1.12 (0.79–1.57), 0.530 0.024
2:others 7 (51.3) 2.17 (1.44–3.27), 0.000   5 (74.5) 2.07 (1.25–3.43), 0.005  
WHO grade       
IV 8 (76.3) 1.73 (1.20–2.50), 0.004 0.915 5 (0.00) 1.46 (1.19–1.80), 0.000 0.143
II–III 3 (87.0) 2.38 (0.30–18.82), 0.411   3 (88.1) 2.17 (0.42–11.28), 0.355